Guggenheim Capital LLC Sells 10,959 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Guggenheim Capital LLC reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 30.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 24,751 shares of the specialty pharmaceutical company's stock after selling 10,959 shares during the quarter. Guggenheim Capital LLC's holdings in Jazz Pharmaceuticals were worth $3,048,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the business. IFP Advisors Inc bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $25,000. Quadrant Capital Group LLC raised its position in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares during the period. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at $28,000. Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $29,000. Finally, Jones Financial Companies Lllp lifted its position in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 130 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Up 0.7 %

JAZZ stock traded up $0.81 during trading on Friday, hitting $109.79. The company had a trading volume of 150,668 shares, compared to its average volume of 1,006,875. The firm has a 50-day moving average price of $125.13 and a 200-day moving average price of $122.18. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market cap of $6.67 billion, a price-to-earnings ratio of 15.46, a PEG ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06.

Analyst Ratings Changes

Several equities research analysts recently weighed in on JAZZ shares. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their target price for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their price target for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Piper Sandler reissued an "overweight" rating and set a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $187.71.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,736 shares of company stock worth $4,023,305. 4.20% of the stock is currently owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.